Formulation Strategies and Evaluation Approaches for Drug-Loaded Paper Tablets in Type 2 Diabetes Management.

Abstract

Diabetes mellitus Type 2 (T2DM) represents a major global health challenge and constitutes approximately 90-95% of all global cases of diabetes. The complex multifactorial pathophysiology of T2DM (i.e., insulin resistance, progressive ?-cell dysfunction, impaired incretin effect, increased renal glucose reabsorption) requires a multidrug therapeutic approach with the use of various drugs that target each of these metabolic defects through multiple routes of administration. Although orally administered solid dosage forms (i.e., tablets) are commonly used in the therapy for T2DM, they usually present several problems with respect to: delayed disintegration when taking glass (tablets), variability of dissolution between individual dose units, gastrointestinal distress when using tablets due to the method of delivery, and poor therapeutic adherence by patients taking a high dose or multiple drug regimen. Drug loaded paper tablets are a novel orally administered drug delivery platform made from cellulose that aims to overcome the issues associated with conventional orally administered tablets. Drug loaded paper tablets use a porous fibrous matrix of cellulose (plant-based, nanocellulose, or bacterial cellulose) that allows for the rapid and capillary driven absorption of liquid, high surface area, and tunable diffusion path lengths. Advanced methods of functionalizing the drug loaded paper tablet (e.g., cross-linking, polymer grafting, and incorporation of nanocarriers) can allow for more precise regulation of the amount of drug loaded and released over time. In addition, drug loaded paper tablets can support multiple drugs being incorporated via solvent impregnation, dip coating, ink jet printing, and electrospinning, thus allowing for both fixed dose combination products and personalized multi-drug therapy products for patients with T2DM. Multiple formulation strategies can be employed with different classes of antidiabetic agents (e.g. Metformin, Sitagliptin, Canagliflozin, Liraglutide, and Pioglitazone) which illustrate the versatility of a drug loaded paper tablet matrix for formulating drugs that are poorly soluble, lipophilic, and/or high-dose peptide-based.

Keywords

Drug-Loaded Paper Tablets, Type 2 Diabetes Management, Formulation Strategies,

Introduction

1.1       Overview of the Global Burden and Pathophysiology of Type 2 Diabetes Mellitus (T2DM)

Type 2 diabetes mellitus (T2DM) has been recognized as one of the major public health issues of the 21st century on a global level. About 90–95% of diagnosed cases of diabetes worldwide fall under T2DM, and this number continues to increase at an alarming rate due to urbanization, lack of physical activity, obesity, and ageing of the population [1]. In addition to the increasing burden of T2DM, many of the world's low-and middle-income countries continue to face increasing strains on their healthcare systems. The continued presence of chronic hyperglycemia associated with the presence of T2DM results in long-term damage, dysfunction, and failure of multiple organs with the most common targets being the eyes, kidney, nerves, heart, and blood vessels [2]. Pathophysiological, T2DM is a complex, heterogeneous metabolic disorder characterized by the presence of chronic hyperglycemia due to a combination of insulin resistance and gradually progressing dysfunction/failure of the pancreatic β-cells [3]. Insulin resistance primarily occurs in the peripheral tissues of skeletal muscle and adipose tissue, reducing glucose uptake and utilization from the bloodstream [4]. In addition, excessive hepatic gluconeogenesis also plays a role in contributing to increased fasting plasma glucose levels. In time, pancreatic β-cell failure increases insulin secretion, compounding the existing glycemic dysregulation [5]. Aside from those described above, impaired action of the incretin hormones (most notably GLP-1) reduces glucose-induced insulin secretion. In contrast, renal glucose reabsorption increased because of sodium-glucose transporter type 2 (SGLT2) results in significant elevations of serum glucose levels [6].

2.         Paper Tablet Technology: Emerging Oral Drug Delivery Platform

Using a porous fibrous matrix to hold active pharmaceutical ingredients (APIs), paper tablets are a completely new oral drug delivery system with their cellulose base designed for rapid and modulated release of drugs [7]. Paper tablets do not use mechanical disintegration, followed by dissolution, as do conventional, compressed tablets; rather, their inherent porosity allows for immediate penetration of liquids after contact and subsequent diffusion of the drug out of the tablet. Structurally, these systems are based on a three-dimensional network of interconnected cellulose microfibers, providing a large surface area with many capillaries for capillary-driven fluid to be rapidly transported after the tablets meet intestinal fluid [8]. The large wettability of cellulose matrices significantly decreases lag time and provides a more uniform kinetics profile for the active ingredient after the tablet has been put into contact with intestinal fluid. In addition to their ability to allow precise formulation of drugs, varying surface functionalization, polymer coating, or crosslinking allows precise control over drug loading and release characteristics [9]. Thus, it is possible to tailor paper tablets to provide rapid or sustained release of the drug in patients with T2DM. Paper tablets hold promise for the future of multidrug therapy in T2DM. Their porous nature allows for evenly distributing multiple APIs within one matrix, enabling fixed-dose combinations to target the many pathophysiological abnormalities characteristic of T2DM [10]. Furthermore, because T2DM is characterized by its multifaceted components, often referred to as the "ominous octet," paper tablets provide a logical method to deliver combination therapy with excellent dissolution efficiency while simultaneously reducing the number of doses taken throughout a day's time frame [11].

3.    Materials Used in Paper Tablet Matrices

3.1  Plant Cellulose

Plant-derived cellulose is a linear β (1→4)-linked D-glucan polymer widely used in pharmaceutical matrices due to its excellent mechanical integrity, biocompatibility, and biodegradability [12]. The extensive hydrogen bonding within cellulose chains provides structural rigidity and tensile strength, making it suitable for paper-based dosage forms. Its hydrophilic hydroxyl groups enable rapid hydration and swelling upon exposure to gastrointestinal fluids, promoting efficient drug diffusion. In addition, cellulose is renewable and sustainable, aligning with green pharmaceutical manufacturing principles. For multidrug therapy in Type 2 diabetes mellitus (T2DM), plant cellulose matrices can uniformly accommodate multiple active pharmaceutical ingredients (APIs), supporting combination therapy strategies targeting diverse metabolic defects [13].

3.2       Nanocellulose

Nanocellulose includes cellulose nanocrystals (CNC) and cellulose nanofibrils (CNF), characterized by nanoscale dimensions and exceptionally high surface area [14]. These materials exhibit superior tensile strength and allow tunable pore architecture, which directly influences diffusion pathways and release kinetics. The large surface-to-volume ratio enhances drug adsorption capacity and enables controlled drug loading. In multidrug systems, nanocellulose can facilitate spatial distribution of APIs within the matrix, minimizing drug–drug interaction while maintaining synchronized or sequential release profiles [15].

3.3       Bacterial Cellulose

Bacterial cellulose, biosynthesized by Gluconacetobacter species, is highly pure, nanofibrillar, and mechanically robust [16]. Its three-dimensional porous network and high crystallinity provide excellent drug entrapment and controlled-release characteristics. Due to its high water-holding capacity and structural uniformity, bacterial cellulose is particularly suitable for sustained-release applications in chronic diseases such as T2DM. However, large-scale production remains a limitation, affecting cost-effectiveness and industrial scalability [17].

3.4       Functionalization Strategies

Surface modification strategies—including carboxylation, esterification, polyethylene glycol (PEG) grafting, mucoadhesive polymer integration (e.g., chitosan), and hydrophobic surface modification—enable fine control over drug binding affinity, wettability, matrix stability, and mechanical strength [18]. These physicochemical modifications regulate diffusion behavior and allow differential release of multiple APIs from a single platform. Such tunability is critical in addressing the multifactorial pathophysiology of T2DM described in the “ominous octet” model, reinforcing the rationale for multidrug therapy through advanced paper tablet matrices.

4.         Drug Loading Techniques

Efficient drug incorporation into cellulose-based paper matrices is critical for achieving reproducible dose uniformity, optimized release kinetics, and compatibility with multidrug therapy in Type 2 diabetes mellitus (T2DM). Various loading techniques have been explored to enhance drug entrapment efficiency, content uniformity, and scalability.

4.1       Solvent Impregnation

Solvent impregnation is one of the simplest and most widely used techniques for drug loading into porous cellulose matrices. In this method, the paper matrix is immersed in a drug solution, allowing capillary-driven absorption into the interconnected fibrous network [19]. Drug deposition occurs upon solvent evaporation, resulting in homogeneous distribution within the matrix pores. The method is cost-effective, requires minimal instrumentation, and is suitable for hydrophilic antidiabetic agents. However, drug crystallization during drying may influence release kinetics and stability [20].

4.2       Dip-Coating

Dip-coating involves controlled immersion of the paper to substrate into a drug solution followed by withdrawal at a predefined speed. The withdrawal rate directly influences coating thickness and drug deposition uniformity according to Landau–Levich principles [21]. This technique provides improved control over surface drug loading compared to passive impregnation and is adaptable for sequential coating in multidrug systems. Dip-coating also enables layering strategies to achieve biphasic or sustained release profiles.

4.3       Inkjet Printing

Inkjet printing is an advanced, precision-based loading approach that allows deposition of microdroplets of drug solution onto predefined areas of the matrix [22]. This technique enables accurate micro-dosing, minimal drug wastage, and batch-to-batch reproducibility. Importantly, inkjet printing supports personalized medicine by enabling patient-specific dose adjustment and multidrug patterning within a single dosage form. It is particularly advantageous for potent drugs requiring precise dosing control [23].

4.4       Electrospinning

Electrospinning produces nanofibrous drug–polymer mats with extremely high surface area and controlled fiber morphology. Drugs can be molecularly dispersed in an amorphous state within electro spun fibers, significantly enhancing dissolution rate and bioavailability [24]. When integrated with paper substrates, electro spun layers can provide rapid-release or modified-release functionality. This approach is especially relevant for poorly water-soluble antidiabetic agents requiring solubility enhancement [25]. Collectively, these loading techniques enable tailored drug distribution, controlled diffusion pathways, and flexible multidrug incorporation in advanced paper tablet systems.

5.         Formulation Strategies for Antidiabetic Drugs

 The multifactorial pathophysiology of Type 2 diabetes mellitus (T2DM), as described in the “ominous octet” model, necessitates rational formulation strategies to accommodate diverse physicochemical and pharmacokinetic profiles of antidiabetic agents within paper tablet matrices.

5.1       Biguanides (Metformin)

Metformin remains the first-line therapy in T2DM. However, its high dose requirement (500–2000 mg/day) and associated gastrointestinal irritation present formulation challenges [26]. In paper-based matrices, multilayer stacking techniques can distribute high drug load across stacked cellulose sheets, ensuring uniformity and mechanical stability. Controlled crosslink density within the matrix regulates swelling behavior and diffusion pathways, enabling sustained-release modification to minimize peak plasma fluctuations and GI side effects [27].

5.2       DPP-4 Inhibitors (e.g., Sitagliptin)

Sitagliptin is a low-dose agent with favorable aqueous solubility, making it suitable for precision loading via inkjet printing. Its low dose requirement allows for accurate micro-deposition with minimal drug wastage. Incorporation into mucoadhesive cellulose–chitosan matrices can prolong gastrointestinal residence time and improve absorption efficiency [28].

5.3       SGLT2 Inhibitors (e.g., Canagliflozin)

Canagliflozin exhibits lipophilic characteristics and limited aqueous solubility. Formulation strategies include hydrophobic surface modification of cellulose matrices to improve compatibility, nanocarrier incorporation (e.g., lipid nanoparticles), and electro spun solid dispersions to enhance dissolution rate and bioavailability [29]. Nanocellulose embedding further supports controlled diffusion of hydrophobic agents.

5.4       GLP-1 Receptor Agonists

Peptide-based GLP-1 receptor agonists such as Liraglutide are prone to enzymatic degradation and instability in the gastrointestinal environment. Paper tablet platforms can integrate lipid nanoparticle encapsulation and protective polymer coatings to enhance stability. Enzyme-resistant matrices and pH-responsive coatings further safeguard peptide integrity until reaching the absorption site [30].

5.5       Thiazolidinediones (Pioglitazone)

Pioglitazone suffers from poor aqueous solubility. Solubility enhancement strategies include formation of solid dispersions, cyclodextrin inclusion complexes, and nanocellulose-based embedding to increase surface area and improve dissolution kinetics [31].

6.    Drug Release Mechanisms

Immediate Release

Immediate-release profiles are achieved through rapid diffusion of drug molecules from hydrophilic porous cellulose matrices. Upon contact with gastrointestinal fluids, capillary action facilitates instant hydration and dissolution, leading to accelerated drug liberation [32].

Diffusion-Controlled Release

Diffusion-controlled release is governed by Fiskian transport through the hydrated polymer network. Crosslink density, pore size, and matrix thickness influence drug mobility and release kinetics. Hydrophobic modifications and multilayer architectures further modulate diffusion pathways, enabling sustained or biphasic drug release suitable for multidrug T2DM therapy [33].

Drug Release Mechanisms

Understanding drug release mechanisms from cellulose-based paper tablets is critical for optimizing therapeutic performance in multidrug management of Type 2 diabetes mellitus (T2DM). The porous architecture, hydrophilicity, and modifiable crosslinked network of cellulose matrices directly influence release kinetics and drug transport behavior.

Immediate Release

Immediate release from paper tablet systems is primarily driven by rapid capillary uptake of gastrointestinal fluids into the hydrophilic porous matrix. The interconnected fibrous network enables instant hydration and swelling, allowing drug molecules deposited on fiber surfaces or within pores to dissolve and diffuse rapidly into the surrounding medium [34]. This mechanism is particularly advantageous for drugs requiring rapid onset of action, such as postprandial glucose regulators. High surface area and minimal diffusion barriers distinguish paper matrices from conventional compressed tablets, which require disintegration prior to dissolution [35].

Diffusion-Controlled Release

Diffusion-controlled release predominates when drugs are entrapped within a crosslinked or partially modified cellulose network. Drug transport follows Fiskian diffusion through hydrated polymer channels, where matrix crosslinking density, pore size distribution, and thickness determine the effective diffusion coefficient [36]. Increased crosslink density reduces swelling and narrows diffusion pathways, thereby prolonging release duration. This approach is valuable for sustained glycemic control in chronic T2DM therapy, minimizing dosing frequency and plasma concentration fluctuations.

Nanocarrier-Mediated Sustained Release

Nanocarrier-mediated systems incorporate drug-loaded nanoparticles (e.g., lipid nanoparticles, polymeric nanospheres, or nanocrystals) within the cellulose matrix. Drug release occurs in two sequential phases: initial diffusion from nanoparticles into the surrounding matrix, followed by transport through the porous scaffold [37]. This dual barrier mechanism enables prolonged and controlled release profiles. Such systems are particularly useful for lipophilic or unstable antidiabetic agents requiring protection and solubility enhancement.

 Drug Release Kinetic Models

Mathematical modeling is essential to characterize release behavior. Common kinetic models include:

• Zero-order kinetics, where drug release occurs at a constant rate independent of concentration.
• First-order kinetics, where release rate is proportional to remaining drug concentration.
• Higuchi model, describing drug diffusion from a homogeneous matrix as a square-foot time-dependent process [34].
• Korsmeyer–Peppas model, used to analyze anomalous (non-Fiskian) transport and determine release exponent (n).
• Hixson–Crowell model, accounting for changes in surface area and particle size during dissolution.

Porous cellulose-based systems frequently conform to Higuchi diffusion kinetics due to their matrix-controlled release mechanism and high surface-area architecture [38,39]. Understanding these models allows rational design of multidrug paper tablet formulations for optimized therapeutic outcomes in T2DM.

7.5 Stability Studies

Stability evaluation of drug-loaded paper tablets is essential to ensure maintenance of physicochemical integrity, therapeutic efficacy, and safety throughout the product’s shelf life. Stability studies are conducted in accordance with International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines, specifically ICH Q1A(R2), which outlines testing conditions for new drug substances and products [40]. Accelerated stability studies are typically performed at 40°C ± 2°C / 75% ± 5% RH for a minimum period of six months to predict long-term stability and identify potential degradation pathways. These conditions are particularly relevant for cellulose-based paper matrices, which are inherently hygroscopic and susceptible to moisture-induced changes in mechanical and release properties [41]. Long-term stability studies are generally conducted at 25°C ± 2°C / 60% ± 5% RH (or climatic zone–specific conditions such as 30°C / 65% RH for Zone IV countries), depending on the target market [42].

Key evaluation parameters include:

• Drug content assay: Quantitative determination of API concentration to assess chemical stability and detect degradation of products.
• Dissolution profile: Comparative in vitro release studies to evaluate any alteration in drug release kinetics over time. Similarity factor (f2) analysis is commonly applied to compare initial and stored samples [43].
• Mechanical integrity: Assessment of tensile strength, flexibility, and structural robustness of the paper matrix, as moisture exposure may weaken fibrous bonding.
• Moisture sensitivity: Determination of moisture uptake using gravimetric analysis or Karl Fischer titration, as increased water content may accelerate hydrolysis or alter diffusion pathways within the matrix [44].

 For multidrug paper tablets intended for Type 2 diabetes management, stability studies are particularly critical due to potential drug–drug interactions and differences in hygroscopicity among incorporated APIs. Comprehensive stability profiling ensures consistent therapeutic performance and regulatory compliance.

8.         Clinical and Regulatory Considerations

Drug-loaded paper tablets intended for Type 2 diabetes mellitus (T2DM) management are regulated as oral solid dosage forms under the frameworks of the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Although the substrate differs from conventional compressed tablets, regulatory expectations remain aligned with established standards for quality, safety, and efficacy [45,46].

Regulatory Requirements

Good Manufacturing Practice (GMP) validation:

Manufacturing processes must comply with current GMP requirements to ensure reproducibility, batch-to-batch uniformity, and contamination control. Attention is required for solvent handling, drying processes, and uniform API deposition within porous matrices [47].

Toxicological evaluation of crosslinkers and modifiers:

Since paper tablet matrices may incorporate crosslinking agents, surface modifiers, or nanocarriers, comprehensive toxicological assessment is mandatory. Residual crosslinkers, solvent traces, and degradation by-products must meet permissible exposure limits. Biocompatibility studies, including cytotoxicity and oral toxicity testing, are essential for novel excipients or chemically modified cellulose systems [48].

Bioequivalence studies:

For products intended as generic or reformulated versions of approved antidiabetic drugs, in vivo bioequivalence studies are required to demonstrate comparable pharmacokinetic parameters (C-max, T-max, and AUC) relative to reference listed drugs. The porous architecture and modified release behavior of paper tablets necessitate careful in vitro–in vivo correlation (IVIVC) development [49].

Stability validation:

Long-term and accelerated stability studies must be conducted in accordance with ICH Q1A(R2) guidelines to establish shelf life and packaging requirements, especially considering the hygroscopic nature of cellulose-based systems [50].

Scalability Strategies

Industrial translation of paper tablet technology requires scalable and reproducible manufacturing approaches:

• Roll-to-roll coating: Enables continuous large-scale impregnation or coating of cellulose substrates with drug solutions, improving throughput and cost-efficiency.
• Automated inkjet printing: Facilitates high-precision, programmable multidrug deposition suitable for personalized dosing and fixed-dose combinations [51].
• Controlled substrate thickness: Standardization of paper thickness and porosity ensures consistent drug loading, mechanical integrity, and predictable diffusion kinetics.

Collectively, adherence to regulatory standards combined with scalable fabrication strategies is critical for successful clinical translation of multidrug paper tablets in T2DM therapy.

9.         Challenges

Despite promising attributes, drug-loaded paper tablets face several formulation and translational challenges in Type 2 diabetes mellitus (T2DM) therapy.

High drug loading (e.g., metformin):

Metformin requires high daily doses (up to 2000 mg), posing limitations in porous cellulose matrices due to saturation of adsorption sites and compromised mechanical strength at elevated loading levels [52]. Achieving uniform distribution without crystallization remains technically demanding.

Hygroscopicity and moisture instability:

Cellulose-based substrates are inherently hydrophilic and prone to moisture uptake, which may alter mechanical integrity, drug stability, and diffusion kinetics. Moisture-induced hydrolysis or polymorphic transitions of APIs can further compromise stability under accelerated conditions [53,54].

Mechanical fragility:

Thin paper matrices may exhibit reduced tensile strength and susceptibility to tearing during handling, packaging, and transportation. Optimization of fiber density, crosslinking, and multilayer stacking is required to enhance structural robustness [55].

Gastrointestinal (GI) variability:

Variations in gastric pH, motility, and intestinal transit time can influence hydration rate and drug diffusion from porous systems. Establishing robust in vitro–in vivo correlation (IVIVC) is therefore essential [56].

Regulatory classification:

Although regulated as oral solid dosage forms, the unconventional architecture may raise questions regarding excipient safety, nanomaterial incorporation, and modified-release claims under frameworks of agencies such as the U.S. Food and Drug Administration and the European Medicines Agency [57,58].

10.       Future Perspectives

 Future research directions aim to enhance therapeutic precision and patient-centric design:

• Smart glucose-responsive release systems: Integration of glucose-sensitive polymers capable of modulating drug release in response to glycemic fluctuations [59].
• pH-targeted intestinal delivery: Application of enteric coatings or pH-responsive matrices to optimize intestinal absorption and reduce gastric irritation.
• Integrated biosensor-based systems: Combination of biosensors with drug matrices for feedback-regulated dosing platforms.
  • Personalized on-demand printing: Advanced  automated inkjet printing for individualized multidrug therapy [60].
  • Hybrid nanocellulose–nanocarrier matrices: Synergistic integration of nanocellulose scaffolds with lipid or polymeric nanoparticles to improve solubility, stability, and sustained release [61].

CONCLUSION

Drug-loaded paper tablets represent a promising next-generation oral drug delivery platform for T2DM management. Their cellulose-based porous matrices enable rapid dissolution, controlled release modulation, dose flexibility, and environmental sustainability. Advanced loading techniques such as inkjet printing and electrospinning permit precision formulation tailored to diverse antidiabetic drugs. Comprehensive physicochemical, mechanical, biological, and regulatory evaluations support feasibility; however, challenges related to high drug loading, moisture sensitivity, and industrial scalability persist. Continued interdisciplinary research integrating polymer science, pharmaceutical technology, and clinical pharmacology is essential for successful clinical translation and regulatory acceptance of this innovative multidrug platform.

?REFERENCES

1. International Diabetes Federation. IDF Diabetes Atlas, 10th ed. Brussels: IDF; 2021.
2. American Diabetes Association. Standards of Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1): S1–S291.
3. Bailey CJ, Turner RC. Metformin. N. Engl Med. 1996; 334:574–579.
4. DeFronzo RA. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58:773–795.
5. DeFronzo RA. Banting Lecture 2008: The triumvirate to the ominous octet. Diabetes. 2009;58(4):773–795.
6. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physio Rev. 2013; 93:137–188.
7. American Diabetes Association. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2023;46(Suppl 1): S140–S157.
8. DeFronzo RA. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58:773–795.
9. Ahmed S, et al. Cellulose-based drug delivery systems. Carbohydras Plym. 2022.
10. Aulton ME, Taylor KMG. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines.5th ed.
11. Bhardwaj N, Kundu SC. Electrospinning: A fascinating fiber fabrication technique. Biotechnology Adv. 2010.
12. Colombo P, et al. Drug release modulation by porous matrices. J Control Release. 2012.
13. DeFronzo RA. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58:773–795.
14. Klemm D, et al. Cellulose: Fascinating biopolymer and sustainable raw material. Ange Chem Int. Ed. 2005.
15. Aulton ME, Taylor KMG. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines.5th ed.
16. Moon RJ, et al. Cellulose nanomaterials review. Chem Soc Rev. 2011.
17. Lin N, Dufresne A. Nanocellulose in biomedicine. Eury Plym J. 2014.
18. Czaja W, et al. Microbial cellulose—the natural power to heal wounds. Biomaterials. 2006.
19. Joali AF, et al. Bacterial cellulose production and application. Appl. Microbial Biotechnology. 2016.
20. Sannino A, et al. Functionalized cellulose matrices for drug delivery. J Appl. Plyms. 2009.
21. Ahmed S, et al. Cellulose-based drug delivery systems. Carbohydras Plym. 2022.
22. Aulton ME, Taylor KMG. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines.5th ed.
23. Scriven LE. Physics and applications for dip coating. AIChE J. 1988.
24. Scouters N, et al. Inkjet printing for pharmaceutical applications. Int J Pharm. 2011.
25. Daly R, et al. Inkjet printing for drug delivery and personalized dosing. Adv Drug Deliv Rev. 2015.
26. Bhardwaj N, Kundu SC. Electrospinning: A fascinating fiber fabrication technique. Biotechnology Adv. 2010.
27. Huang ZM, et al. Electro spun nanofibers for drug delivery systems. J Control Release. 2003.
28. DeFronzo RA. From the triumvirate to the ominous octet. Diabetes. 2009; 58:773–795.
29. Ahmed S, et al. Cellulose-based drug delivery systems. Carbohydrate Plym. 2022.
30. Bailey CJ, Turner RC. Metformin. N. Engl J Med. 1996.
31. Aulton ME, Taylor KMG. Aulton’s Pharmaceutics. 5th ed.
32. Scouters N, et al. Inkjet printing for pharmaceutical applications. Int J Pharm. 2011.
33. Huang ZM, et al. Electro spun nanofibers for drug delivery. J Control Release. 2003.
34. Drucker DJ. The biology of incretin hormones. Cell Mehtab. 2006.
35. Loftsson T, Duchêne D. Cyclodextrins and their pharmaceutical applications. Int J Pharm. 2007.
36. DeFronzo RA. From the triumvirate to the ominous octet. Diabetes. 2009; 58:773–795.
37. Ahmed S, et al. Cellulose-based drug delivery systems. Carbohydras Plym. 2022.
38. Bailey CJ, Turner RC. Metformin. N. Engl J Med. 1996.
39. Aulton ME, Taylor KMG. Aulton’s Pharmaceutics. 5th ed.
40. Scouters N, et al. Inkjet printing for pharmaceutical applications. Int J Pharm. 2011.
41. Huang ZM, et al. Electro spun nanofibers for drug delivery. J Control Release. 2003.
42. Drucker DJ. The biology of incretin hormones. Cell Mehtab. 2006.
43. Loftsson T, Duchêne D. Cyclodextrins and their pharmaceutical applications. Int J Pharm. 2007.
44. Ahmed S, et al. Cellulose-based drug delivery systems. Carbohydras Polyp. 2022.
45. Aulton ME, Taylor KMG. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines.5th ed.
46. Siepmann J, Peppas NA. Modeling of drug release from delivery systems. Adv Drug Deliv Rev. 2001.
47. Kumari A, et al., Nanoparticle-based drug delivery systems. Colloids Surf B Bio interfaces. 2010.
48. Higuchi T. Mechanism of sustained action medication. J Pharm Sci. 1963.
49. ICH Q1A(R2). Stability Testing of New Drug Substances and Products. International Council for Harmonization; 2003.
50. Aulton ME, Taylor KMG. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines.5th ed.
51. Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol. 1996.
52. Waterman KC, Adami RC. Accelerated aging studies and moisture effects in pharmaceuticals. Int J Pharm. 2005.
53. Scouters N, et al. Inkjet printing for pharmaceutical applications. Int J Pharm. 2011.
54. ICH Q1A(R2). Stability Testing of New Drug Substances and Products. 2003.
55. FDA. Guidance for Industry: Bioavailability and Bioequivalence Studies. U.S. Food and Drug Administration.
56. EMA. Guideline on the Investigation of Bioequivalence. European Medicines Agency.
57. FDA. Current Good Manufacturing Practice (cGMP) Regulations.
58. ICH Q3C. Impurities: Guideline for Residual Solvents. International Council for Harmonization.
59. Bailey CJ, Turner RC. Metformin. N. Engl J Med. 1996.
60. Aulton ME, Taylor KMG. Aulton’s Pharmaceutics. 5th ed.
61. Siepmann J, Peppas NA. Modeling of drug release. Adv Drug Deliv Rev. 2001.
62. Kumari A, et al., Nanoparticle-based drug delivery systems. Colloids Surf B Bio interfaces. 2010.
63. ICH Q1A(R2). Stability Testing of New Drug Substances and Products. 2003.
64. Waterman KC, Adami RC. Accelerated aging and moisture effects. Int J Pharm. 2005.
65. FDA. Guidance for Industry: Bioavailability and Bioequivalence Studies.
66. EMA. Guideline on the Investigation of Bioequivalence.
67. Gu Z et al. Glucose-responsive materials for diabetes therapy. Nat Rev Mater. 2016.